LVTX Stock LVTX is expected to report earnings to fall -29% to -31 cents per share on May 20

A.I.dvisor
at Tickeron.com
05/19/24
Loading...
LVTX - LAVA Therapeutics NV
LAVA Therapeutics NV Earnings Graph
Q1'24
Est.
$-0.31
Q4'23
Beat
by $0.20
Q3'23
Beat
by $0.15
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.04
The last earnings report on December 31 showed earnings per share of -24 cents, beating the estimate of -44 cents. P/B Ratio (1.356) is normal, around the industry mean (12.558). P/E Ratio (0.000) is within average values for comparable stocks, (151.642). LVTX's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.434). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (10.428) is also within normal values, averaging (241.835). With 47.19K shares outstanding, the current market capitalization sits at 69.40M.
View a ticker or compare two or three
LVTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Yalelaan 62
Phone
+31 850163100
Employees
35
Web
https://www.lavatherapeutics.com